{"entity":{"id":"nct06668792","kind":"trial","name":"An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma","aka":[],"tldr":"A phase 2 trial of BCD-248 in multiple myeloma, run by Biocad, now recruiting.","summary":"An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT06668792 by Biocad, with 100 participants planned, started 2024-12-26 and due to reach its primary completion in 2026-02. Interventions recorded: BCD-248.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06668792","url":"https://clinicaltrials.gov/study/NCT06668792"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["biocad"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06668792","phase":"2","setting":"An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Subjects With Relapsed/Refractory Multiple Myeloma","sponsor":"Biocad","enrolled":100,"outcomes":[]},"route":"/trials/nct06668792/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"company":[{"id":"biocad","kind":"company","name":"Biocad","route":"/companies/biocad/"}]}}